Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786482 | 0.88 | TBXA2R (0.37) | PTGER1TBXA2RCCR5MRGPRX4 | |
| SCHEMBL21786536 | 0.88 | PTGER1 (0.41) | CNR1PTGER1TBXA2RMRGPRX4 | |
| SCHEMBL22791110 | 0.86 | TBXA2R (0.36) | PTGER1TBXA2RCCR5MRGPRX4 | |
| SCHEMBL21786475 | 0.86 | TBXA2R (0.35) | CNR1PTGER1TBXA2RCCR5MRGPRX4 | |
| SCHEMBL22791119 | 0.84 | USP7 (0.38) | USP7CYP1A2METAP2 | |
| SCHEMBL23913056 | 0.83 | TBXA2R (0.35) | PTGER1TBXA2RCCR5MRGPRX4 | |
| SCHEMBL21786498 | 0.83 | SCN9A (0.37) | CNR1XDHCCR5USP7 | |
| SCHEMBL21786539 | 0.82 | XDH (0.35) | XDHUSP7CYP1A2METAP2 | |
| SCHEMBL21786540 | 0.82 | USP7 (0.37) | CNR1USP7CYP1A2METAP2 | |
| SCHEMBL21786542 | 0.80 | USP7 (0.35) | CNR1XDHPTGER1TBXA2RCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | CNR1 2368/4885XDH 3318/4885PTGER1 4862/4885 |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | CNR1 2368/4885XDH 3318/4885PTGER1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.